Le Lézard
Classified in: Ebola virus, Health, Science and technology
Subjects: CCA, BFA

Aethlon Medical to Release Financial Results for the Second Quarter Fiscal Year 2018 and Host Conference Call on November 2, 2017



SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the second quarter fiscal year 2018 ended September 30, 2017 at 4:15pm eastern time on Thursday, November 2, 2017.

Management will host a conference call on Thursday, November 2, 2017 at 4:30pm eastern time to review financial results and corporate highlights. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical Inc., conference call. The conference call will also be available through a live webcast at www.aethlonmedical.com. Details for the webcast may be found on the Company's IR events page at http://ir.aethlonmedical.com.

A replay of the call will be available approximately one hour after the end of the call through November 9, 2017. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10114031.

About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com

 

SOURCE Aethlon Medical, Inc.


These press releases may also interest you

at 07:49
Aethlon Medical, Inc. , a therapeutic technology company focused on unmet needs in global health and biodefense, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application Number 14/490,418 ("the '418...

17 jan 2018
SKF's Nomination Committee proposes Hans Stråberg as new Chairman of the Board of AB SKF. Hans Stråberg is Chairman of the Board of Atlas Copco AB, Roxtec AB, CTEK AB, Nikkarit Holding AB; Vice Chairman of the Board of Stora Enso Oyj, Orchid...

16 jan 2018
? CTV's acclaimed Canadian drama series CARDINAL leads Bell Media productions with 12 nominations ?? CraveTV Original Series LETTERKENNY receives nine; the final seasons of Space's ORPHAN BLACK and CTV's 19-2 each receive six ?? Discovery Channel...

16 jan 2018
The SKF Group will publish its full year results on 1 February 2018 and welcomes investors, analysts and members of the media to take part in a conference call, which will be held in English, at 14:00 (Swedish Time), 13:00 (UK Time). To join the...

10 jan 2018
Aethlon Medical, Inc. , a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Sabrina Martucci Johnson to its Board of Directors and to its Audit Committee. Ms. Johnson qualifies...

9 jan 2018
Eisai Co., Ltd. and Merck , known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Eisai's multiple receptor tyrosine kinase...




News published on 30 october 2017 at 07:30 and distributed by: